Eli Lilly, weight loss
Digest more
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027.
Asda Online Doctor said it had seen a 350 per cent increase in demand for Mounjaro since Lilly announced the price rise on Thursday, while London-based MedExpress said it had seen a 40 per cent jump in orders, compared with a normal day. MedExpress’s website slowed as customers rushed to buy the drug, because of the “significant uptick in traffic”.